mrc respiratory development and disease consortium dr matt hind and dr charlotte dean national heart...
TRANSCRIPT
MRC Respiratory MRC Respiratory Development and Development and Disease ConsortiumDisease ConsortiumDr Matt Hind and Dr Charlotte Dean
National Heart and Lung Institute, Imperial College and MRC Harwell
BackgroundBackground
Respiratory disease is common and increasing in prevalence
WHO predicts COPD rise from 5th to 3rd commonest cause of death by 2020
COPD costs NHS in excess of £1bn annually
Lung cancer common, highest mortality
Mismatch between funding available and prevalence of disease
Few effective treatments for chronic respiratory disease
Consortium membersConsortium members
National Consortium across UK (IC, UCL, Cambridge, Southampton, Nottingham, Newcastle and Sheffield (28 PIs)
International expertise in mouse lung phenotyping and disease modelling
Strong link between bench and clinic
Translational pipelineTranslational pipeline
Mutant studies
Disease Modelling
Human tissue studies (primary cell culture, tissue modelling and ex vivo models)
Link with existing NIHR funded Respiratory BRU and BRC’s with mission of first into man studies with mission of first into man studies
Strategic aimsStrategic aims
To prioritize target genes identified from investigator led research
Secondary phenotyping of selected mutants eg asthma; flexivent lung function, immunological profiling, epithelial barrier integrity
gene function from development through to adulthood and the role in established disease models
develop high throughput phenotype screening (WBP)
Research AimsResearch Aims
models of bronchopulmonary dysplasia or prematurity
models of asthma
models of COPD/emphysema
models of lung cancer
models of acute lung injury
models of fibrosis
models of lung regeneration
Plan of actionPlan of actionInvestigator led phenotyping tailored to research interest but overlap between groups and outside consortium
both airway and parenchymal specific cre drivers
use of conditional and inducable conditional tissue (CCSP-cre, SPC-cre) specific and other suitable drivers eg myeloid specific
To maintain MRC lung database for consortium members to upload info
Delivery of strategic Delivery of strategic aimsaims
Prority of initial genes where facilities (funding and space) exists to take mice currently
Selection of candidate genes based on consensus and equity across disease areas
Provision of mutants
Feedback of metrics
